Evidence map›Paper›PMID 32328073›Full record

ArticleFrontiers in immunology2020

Determining Whether Agonist Density or Agonist Number Is More Important for Immune Activation via Micoparticle Based Assay.

Peter Deak, Flora Kimani, Brittney Cassaidy, Aaron Esser-Kahn

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Frontiers in immunology, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
0.4field-weighted citation impact, top 41% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 5 citations in OpenAlex.

  1. Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 1 institution in 1 country.

Peter DeakPritzker School of Molecular Engineering, The University of Chicago, Chicago, IL, United States.
Flora KimaniPritzker School of Molecular Engineering, The University of Chicago, Chicago, IL, United States.
Brittney CassaidyPritzker School of Molecular Engineering, The University of Chicago, Chicago, IL, United States.
Aaron Esser-KahnPritzker School of Molecular Engineering, The University of Chicago, Chicago, IL, United States.
University of Chicago · US

Funding

Determining the Molecular Mechanism of Covalently Linked TLR AgonistsU01AI124286 · NIAID · UNIVERSITY OF CHICAGO · PI ESSER-KAHN, AARON P · 2016 to 2020
$3.2M
Microparticle Induced Synergistic Toll-Like Receptor Activation Effect on Dendritic Cell Hyper-Responsive Sub-PopulationsF32AI147517 · NIAID · UNIVERSITY OF CHICAGO · PI DEAK, PETER · 2019 to 2020
$127k
NIAID NIH HHS F32 AI147517NIAID NIH HHS U01 AI124286
6 · The paper itself

Abstract

It is unknown if surface bound toll-like-receptor (TLR) agonists activate cells via density or total molecular number. To answer this question, we developed a TLR agonist surface conjugated polystyrene microparticle (MP) system. Using a library of MPs with varying TLR agonist density and number, we simultaneously observed innate immune cell MP uptake and TNFα expression using ImageStream flow cytometry on a cell by cell basis. The data shows that total TLR number and not density drives cellular activation with a threshold of approximately 10

Indexed as

AnimalsCell AdhesionCells, CulturedHumansImmunity, InnateImmunoassayLipid ALymphocytesMicroplasticsOligopeptidesPolystyrenesToll-Like Receptor 2Toll-Like Receptor 4Toll-Like Receptor 9Toll-Like ReceptorsTumor Necrosis Factor-alphaLipid AMicroplasticsmonophosphoryl lipid AOligopeptidesPAM2-CSK4PolystyrenesToll-Like Receptor 2Toll-Like Receptor 4Toll-Like Receptor 9Toll-Like ReceptorsTumor Necrosis Factor-alphaactivation thresholdinnate immunityIn vitro quantificationmicroparticletoll-like-receptor

Identifiers

PMID32328073
PMCPMC7161694
OpenAlexW3016047760

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.